We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Immune Response Analysis to Influenza Vaccine in Elderly Aged Over 65 Years (Expand IDWP21)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2011 by Hospices Civils de Lyon.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01289535
First Posted: February 3, 2011
Last Update Posted: December 30, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Hospices Civils de Lyon
  Purpose

This study is the first step in a clinical research program that aims to study the immune response to influenza vaccine in the elderly and then to propose a new method of administering the vaccine.

Influenza can cause severe complications in patients at risk (elderly and subjects vulnerable because of a chronic underlying disease). Over 90% of deaths related to influenza occur in people aged over 65 years.

Vaccination is the most effective way to prevent infection. The World Health Organization recommends annual immunization for people at risk, including all persons aged over 65 years, to reduce the risk of morbidity and mortality related to influenza.

However, the immune response to influenza vaccine appears to be lower in elderly than in young people.


Condition Intervention Phase
Immune Response Procedure: Blood sample Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Immune Response Analysis to Influenza Vaccine in Elderly Aged Over 65 Years

Resource links provided by NLM:


Further study details as provided by Hospices Civils de Lyon:

Primary Outcome Measures:
  • antibody rates after influenza vaccination [ Time Frame: up to 3 months after vaccination ]

Estimated Enrollment: 750
Study Start Date: November 2010
Estimated Study Completion Date: April 2012
Estimated Primary Completion Date: April 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: antibody rates Procedure: Blood sample
Blood sample of 7 ml

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   65 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Subject aged 65 years or over
  • Influenza vaccination without adjuvant, within 3 weeks and 3 months before inclusion visit
  • Legal capacity to consent
  • Subject had given written consent before his participation

Exclusion Criteria:

  • Adjuvanted influenza vaccine (e.g: Fluad, Gripguard)
  • Live vaccines within 3 weeks before and after influenza vaccination
  • Inactivated vaccines within 2 weeks before and after influenza vaccination
  • Chronic disease non-stabilized under treatment
  • Severe malnutrition in the opinion of the investigator
  • Congenital immunodeficiency
  • Chemotherapy or radiotherapy over the last 6 months
  • Immunosuppressive therapy or corticosteroid (daily dose of prednisone or equivalent >/= 20 mg/d over 14 days) from 1 month before vaccination until the study visit
  • Participation in another clinical study that could interfere with the present study
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01289535


Contacts
Contact: Catherine GOUJON, Dr +33 478 86 41 25 catherine.goujon@chu-lyon.fr

Locations
France
Unité de Recherche Clinique en Immunologie Lyon Sud (URCI-LS) et Service d'Immunologie clinique et allergologie Recruiting
Pierre-Bénite, France, 69495
Contact: Catherine GOUJON, Dr    +33 478 86 41 25    catherine.goujon@chu-lyon.fr   
Principal Investigator: Catherine GOUJON, Dr         
Sponsors and Collaborators
Hospices Civils de Lyon
  More Information

Responsible Party: Hospices Civils de Lyon
ClinicalTrials.gov Identifier: NCT01289535     History of Changes
Other Study ID Numbers: 2010.621
First Submitted: February 2, 2011
First Posted: February 3, 2011
Last Update Posted: December 30, 2011
Last Verified: December 2011

Keywords provided by Hospices Civils de Lyon:
Influenza vaccine
immune response
elderly

Additional relevant MeSH terms:
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases
Vaccines
Immunologic Factors
Physiological Effects of Drugs